Strong second-quarter GDP data will provide some confidence for post-lockdown rebound.

Winstone Wallboards, Tasman Insulation and Pacific CoilCoaters staff about to return.

New forecast: What happens to jobs, GDP and interest rates if elimination doesn't work?

Lockdown costs look bad, but past experience shows we need to factor in the rebound.

Opinion: Things look good in the short term but what about the longer view?

NZX-listed Cavalier has gone back to making wholly woollen carpets.

Pharma company is closing sites in South Auckland that have operated since the 1990s.

"You're a long time dead ... whatever you are doing, make sure it's enjoyable."

Earthworks costing $12m are well under way as publicly funded appeals go in.

Kiwi John Webster has a business making Japanese-style charred wood cladding in Rotorua.

Building boom, dairy prices driving economic confidence around country.

The NZ Defence Force has been with the same provider for more than two decades.

Green push towards net zero emissions could create millions of tonnes of hazardous junk.

Kiwi jewellery maker talks about her invitations to New York and Paris Fashion Weeks.

Why NZX-listed Me Today is buying into a good thing.

Forecast comes as scarcity forces carmakers to scale back production.

Rod Jenden: "We've been through some pretty tough times... I can tell you it's not easy."

NanoLayr says each of its products could become $100m businesses in five years.

'We're very much fighting fit. We're in good shape.' - Taylor on heroic turnaround.

Commissioners sharply rebuke two authorities who opposed Sleepyhead Estate.

Hamish Donkers explains how his friend's trip overseas inspired his e-commerce business.

Former nurse says raise will enable her firm to grow its distribution.

Skyrocketing costs, shortages and delays: here's how to beat the building blues.

It can cost millions to protect Kiwi ingenuity from global theft. Is it worth it?

Firms say domestic demand is holding steady but supply shortages are causing big problems.

Financial Times: AstraZeneca to move production out of Baltimore facility after mix-up.

After both a shortage and glut of chocolate eggs last year, Easter trade is looking good.